Huadong Pharmaceutical (000963.SZ): HDM2020 clinical trial application approved for injection

Zhitongcaijing · 06/26/2025 10:25

Zhitong Finance App News, Huadong Pharmaceutical (000963.SZ) announced that Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd. (“China-US Huadong”), a wholly-owned subsidiary of the company, received the “Drug Clinical Trial Approval Notice” approved by the National Drug Administration (NMPA) and approved the HDM2020 clinical trial application for injection declared by China and the US East China. The relevant indications are: advanced solid tumors.